March 20, 2017: Jazz Pharmaceuticals announced positive efficacy results from two global multicenter studies in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA). JZP-110 demonstrated highly statistically significant differences in the co-primary efficacy endpoints in the TONES 3 study at the 300 mg, 150 mg, 75 mg and 37.5 mg dose arms (Read More….)
Just a handful of technologies deserve to be called “game changers”—and CRISPR-Cas9, the new gene-editing tool, is one of them. Discovered just three years ago, CRISPR is sweeping through labs around the world and researchers are already using it to experiment on diseases like cancer and AIDS, engineer new sources of clean energy, and create (Read More….)
Excellent presentation by Dr. Kevin Folta on biotechnology and GMO foods. Dr Folta makes the connection that humans have been genetically modifying things for hundreds of years and he uses the common dog and cat as an example. Basically Dr. Folta’s presentation breaks down to the idea that a lot of people need to take (Read More….)
Dr. Patrick Paddison’s presentation on what graduate students are now learning regarding CRISPR-Cas9 technology is fascinating. I thought it interesting that in one of the slides my favorite genome sequencing company Illumina is listed as next generation sequencing.
Genome-wide CRISPR-Cas9 gene editing screens – Patrick Paddison, Ph.D.
February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).
SUNBEAM evaluated two (Read More….)
February 14, 2017: Sarepta Therapeutic’s stock has formed a candle over candle reversal after Feuerstein said, “Sarepta Therapeutics is being dragged down unfairly into the price-gouging muck by Marathon Pharmaceuticals.” Source: https://www.thestreet.com/story/14001431/1/defending
January 10, 2017: Baird reiterates a Buy rating on biotechnology firm Sarepta Therapeutics and set a price target of $102. Baird named Sarepta (Read More….)
January 16, 2017: Novogene will buy 10 PacBio Sequel Systems for DNA sequencing services. No terms were disclosed. PacBios sequencing systems are based on its unique Single Molecule, Real-Time (SMRT) technology, and provide an unmatched depth of genetic information through exceptionally long sequencing reads, uniform coverage, and the highest consensus accuracy available today. The technology (Read More….)
Orexigen Therapeutics continues to be the top performing stock since profiled on GuerillaStockTrading.com. Orexigen Therapeutics is up an incredible +74.59%.
Here are the top performing stocks on GuerillaStockTrading.com for the week ending January 13, 2017.
OREX = +74.59% XGTI = +46.26% LPTH = +25.71% EXAS = +24.64% RNVA = +22.22% IMGN = +20.59% OPGN (Read More….)
December 27, 2016: Seattle Genetics announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). The clinical holds were initiated to evaluate the potential risk of (Read More….)